NR4A1 and breast carcinoma: We validated the CA20-based predictions by quantitatively analysing centrosome numbers in human breast carcinoma samples, where we found that indeed CA is more prevalent in luminal B than luminal A tumours, providing a novel insight into the differences between these two hormone-receptor positive molecular subtypes.